Opyl is providing consulting services to Paul Rennie's Paradigm Pharmaceuticals.
OPL chairman, Saurabh Jain, discloses the PAR relationship in an 8 minute interview with Niv Gagan, CEO of Peak Asset Management.
Dagan is OPL's second largest shareholder.
He notes in the interview posted on LinkedIn that he'll be joining OPL directors for dinner.
Paradigm is planning an important Phase 3 clinical trial of it's key iPPS compound in osteo-arthritis.
It seems likely that OPL's AI tech will be used in PAR's trial design.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.161M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50826 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 280103 | 2 |
View Market Depth
| Last trade - 16.21pm 08/08/2025 (20 minute delay) ? |
| OPL (ASX) Chart |
Day chart unavailable